Relay Therapeutics, Inc. Depreciation
Relay Therapeutics, Inc. (RLAY) reported Depreciation of $864.00 thousand for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow › Operating Activities
us-gaap:Depreciation · last filed 2026-08-06
- Relay Therapeutics, Inc. depreciation for the quarter ending 2026-06-30 was $360.00K, a 64.07% decline year-over-year.
- Relay Therapeutics, Inc. depreciation for the quarter ending 2026-03-31 was $504.00K, a 58.28% decline year-over-year.
- Relay Therapeutics, Inc. depreciation for the quarter ending 2025-12-31 was $599.00K, a 55.10% decline year-over-year.
- Relay Therapeutics, Inc. depreciation for the quarter ending 2025-09-30 was $748.00K, a 45.28% decline year-over-year.
- Relay Therapeutics, Inc. depreciation for fiscal 2025 was $3.56M, a 34.90% decline from fiscal 2024.
- Relay Therapeutics, Inc. depreciation for fiscal 2024 was $5.46M, a 3.70% increase from fiscal 2023.
- Relay Therapeutics, Inc. depreciation for fiscal 2023 was $5.27M, a 27.58% increase from fiscal 2022.
- Relay Therapeutics, Inc. depreciation for fiscal 2022 was $4.13M, a 5.22% increase from fiscal 2021.
| Period end | Depreciation 3 month | Depreciation 6 month | Depreciation 9 month | Depreciation 12 month |
|---|---|---|---|---|
| 2026-06-30 | $360.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $864.00K 10-Q · filed 2026-08-06 | $1.46M derived: sum of 3 quarters · filed 2026-08-06 | $2.21M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $504.00K 10-Q · filed 2026-05-05 | $1.10M derived: sum of 2 quarters · filed 2026-05-05 | $1.85M derived: sum of 3 quarters · filed 2026-05-05 | $2.85M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $599.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $1.35M derived: sum of 2 quarters · filed 2026-02-26 | $2.35M derived: sum of 3 quarters · filed 2026-08-06 | $3.56M 10-K · filed 2026-02-26 |
| 2025-09-30 | $748.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $1.75M derived: sum of 2 quarters · filed 2026-08-06 | $2.96M 10-Q · filed 2025-11-06 | $4.29M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | $2.21M 10-Q · filed 2026-08-06 | $3.54M derived: sum of 3 quarters · filed 2026-08-06 | $4.91M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.21M 10-Q · filed 2026-05-05 | $2.54M derived: sum of 2 quarters · filed 2026-05-05 | $3.91M derived: sum of 3 quarters · filed 2026-05-05 | $5.28M derived: sum of 4 quarters · filed 2026-05-05 |
| 2024-12-31 | $1.33M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.70M derived: sum of 2 quarters · filed 2026-02-26 | $4.07M derived: sum of 3 quarters · filed 2026-02-26 | $5.46M 10-K · filed 2026-02-26 |
| 2024-09-30 | $1.37M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | $2.73M derived: sum of 2 quarters · filed 2025-11-06 | $4.13M 10-Q · filed 2025-11-06 | $5.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-06-30 | $1.37M derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-07 | $2.76M 10-Q · filed 2025-08-07 | $4.14M derived: sum of 3 quarters · filed 2026-02-26 | $5.50M derived: sum of 4 quarters · filed 2026-02-26 |
| 2024-03-31 | $1.40M 10-Q · filed 2025-05-05 | $2.77M derived: sum of 2 quarters · filed 2026-02-26 | $4.13M derived: sum of 3 quarters · filed 2026-02-26 | $5.47M derived: sum of 4 quarters · filed 2026-02-26 |
| 2023-12-31 | $1.38M derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | $2.74M derived: sum of 2 quarters · filed 2026-02-26 | $4.07M derived: sum of 3 quarters · filed 2026-02-26 | $5.27M 10-K · filed 2026-02-26 |
| 2023-09-30 | $1.36M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | $2.70M derived: sum of 2 quarters · filed 2024-11-06 | $3.89M 10-Q · filed 2024-11-06 | $5.06M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-06-30 | $1.33M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-06 | $2.53M 10-Q · filed 2024-08-06 | $3.70M derived: sum of 3 quarters · filed 2025-02-26 | $4.73M derived: sum of 4 quarters · filed 2025-02-26 |
| 2023-03-31 | $1.20M 10-Q · filed 2024-05-02 | $2.36M derived: sum of 2 quarters · filed 2025-02-26 | $3.40M derived: sum of 3 quarters · filed 2025-02-26 | $4.35M derived: sum of 4 quarters · filed 2025-02-26 |
| 2022-12-31 | $1.17M derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-26 | $2.20M derived: sum of 2 quarters · filed 2025-02-26 | $3.15M derived: sum of 3 quarters · filed 2025-02-26 | $4.13M 10-K · filed 2025-02-26 |
| 2022-09-30 | $1.03M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | $1.99M derived: sum of 2 quarters · filed 2023-11-02 | $2.96M 10-Q · filed 2023-11-02 | $4.00M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-06-30 | $956.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $1.93M 10-Q · filed 2023-08-08 | $2.96M derived: sum of 3 quarters · filed 2024-02-22 | $3.98M derived: sum of 4 quarters · filed 2024-02-22 |
| 2022-03-31 | $975.00K 10-Q · filed 2023-05-04 | $2.01M derived: sum of 2 quarters · filed 2024-02-22 | $3.02M derived: sum of 3 quarters · filed 2024-02-22 | $3.98M derived: sum of 4 quarters · filed 2024-02-22 |
| 2021-12-31 | $1.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-22 | $2.05M derived: sum of 2 quarters · filed 2024-02-22 | $3.01M derived: sum of 3 quarters · filed 2024-02-22 | $3.92M 10-K · filed 2024-02-22 |
| 2021-09-30 | $1.01M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | $1.97M derived: sum of 2 quarters · filed 2022-11-03 | $2.89M 10-Q · filed 2022-11-03 | $3.80M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-06-30 | $960.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | $1.88M 10-Q · filed 2022-08-04 | $2.79M derived: sum of 3 quarters · filed 2023-02-23 | $3.70M derived: sum of 4 quarters · filed 2023-02-23 |
| 2021-03-31 | $919.00K 10-Q · filed 2022-05-05 | $1.83M derived: sum of 2 quarters · filed 2023-02-23 | $2.74M derived: sum of 3 quarters · filed 2023-02-23 | $3.61M derived: sum of 4 quarters · filed 2023-02-23 |
| 2020-12-31 | $912.00K derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | $1.82M derived: sum of 2 quarters · filed 2023-02-23 | $2.69M derived: sum of 3 quarters · filed 2023-02-23 | $3.55M 10-K · filed 2023-02-23 |
| 2020-09-30 | $913.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-10 | $1.78M derived: sum of 2 quarters · filed 2021-11-10 | $2.64M 10-Q · filed 2021-11-10 | $3.49M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-06-30 | $865.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | $1.72M 10-Q · filed 2021-08-12 | $2.58M derived: sum of 3 quarters · filed 2022-02-24 | $3.21M derived: sum of 4 quarters · filed 2022-02-24 |
| 2020-03-31 | $859.00K 10-Q · filed 2021-05-13 | $1.71M derived: sum of 2 quarters · filed 2022-02-24 | $2.35M derived: sum of 3 quarters · filed 2022-02-24 | |
| 2019-12-31 | $853.00K derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-24 | $1.49M derived: sum of 2 quarters · filed 2022-02-24 | $2.85M 10-K · filed 2022-02-24 | |
| 2019-09-30 | $634.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-12 | $1.99M 10-Q · filed 2020-11-12 | ||
| 2019-06-30 | $1.36M 10-Q · filed 2020-08-27 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| CRISPR Therapeutics AG (CRSP) | $5.390B | -11.68 | |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |